For research use only. Not for therapeutic Use.
ACT-389949 (Cat.No:I017873) is a selective estrogen receptor degrader (SERD) under investigation for the treatment of hormone receptor-positive breast cancer. It works by binding to the estrogen receptor and causing its degradation, leading to inhibition of tumor growth. Clinical trials have shown promising results for ACT-389949 in advanced breast cancer patients.
| Catalog Number | I017873 |
| CAS Number | 1258417-54-7 |
| Molecular Formula | C₂₀H₁₈F₂N₆O₃ |
| Purity | ≥95% |
| Target | Formyl Peptide Receptor (FPR) |
| IUPAC Name | N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide |
| InChI | InChI=1S/C20H18F2N6O3/c1-11-5-4-6-13(7-11)18-17(24-12(2)31-18)19(29)26-15-8-23-28(27-15)9-16-25-14(10-30-16)20(3,21)22/h4-8,10H,9H2,1-3H3,(H,26,27,29) |
| InChIKey | PBTWPEDVIMHJEO-UHFFFAOYSA-N |
| SMILES | CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F |
| Reference | [1]. Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83(3):476-486.<br>[2]. Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173. |
